Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Multiple Sclerosis (MS) patients often complain of cognitive fatigue. There is currently no treatment for this symptom. Fampridine SR is a recently approved medication that improves walking ability and walking speed in MS patients. It is thought that it might have the same positive effect on cognitive fatigue. This study will compare fampridine 10mg twice a day to placebo in order to determine if there is any benefit of this medication for cognitive fatigue in MS.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 64 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males/Females who are ≥ 18 years old and < 65 years old
Capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education
Have a diagnosis of Relapsing Remitting, Secondary Progressive or Primary Progressive MS, as per revised McDonald's Criteria
Have not received steroids in last thirty (30) days or a relapse in the last sixty (60) days, and whose MS is considered stable
Have a PASAT CF z-score that is worse than 1.5 SD below the mean (<-1.5 SD).
Have an Expanded Disability Status Scale (EDSS) of ≤ 7.0
Have given written informed consent prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his/her future medical care
Are capable of performing the requirements of a NP test battery including at least 20/70 near visual acuity by near vision chart, with correction allowed
If female, must neither be pregnant nor breast-feeding
Have cognitive deficits caused by concomitant medication usage or other significant neurological/psychological disease e.g. Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack, Vascular Dementia, Huntington's disease, traumatic brain injury or chronic CNS infection
Have evidence of other medical cause(s) of cognitive impairment
Have evidence of major depression as determined by a positive BDIFS and clinician interview
Have a history of uncontrolled hypertension, tachycardia or cardiovascular or disease
Have a history or current presentation of seizure
Are currently taking compounded 4-aminopyridine or another form of fampridine
Have a known hypersensitivity to any medical or non-medical ingredient of the medication tablet.
Have evidence of renal impairment (creatinine clearance ≤ 80 mL/min)
Are taking medications that are inhibitors of the renal organic cation transporter 2 (OCT2)